Mezzion Pharma Co.,Ltd.

KOSDAQ:A140410 Stock Report

Market Cap: ₩952.8b

Mezzion PharmaLtd Dividends and Buybacks

Dividend criteria checks 0/6

Mezzion PharmaLtd does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0.2%

Buyback Yield

Total Shareholder Yield0.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit

Sep 27
Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit

Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Jun 11
Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking

Mar 04
Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking

We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon

Feb 05
We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon

Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain

Dec 14
Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if A140410's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A140410's dividend payments have been increasing.


Dividend Yield vs Market

Mezzion PharmaLtd Dividend Yield vs Market
How does A140410 dividend yield compare to the market?
SegmentDividend Yield
Company (A140410)n/a
Market Bottom 25% (KR)1.2%
Market Top 25% (KR)3.9%
Industry Average (Pharmaceuticals)1.1%
Analyst forecast (A140410) (up to 3 years)n/a

Notable Dividend: Unable to evaluate A140410's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A140410's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate A140410's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A140410 has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:49
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mezzion Pharma Co.,Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae Hoon ShinHanwha Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Seung Kyu JungKiwoom Securities Co., Ltd.